Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Lantheus (LNTH) and Ardelyx (ARDX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cogent Biosciences (COGT – Research Report), Lantheus (LNTH – Research Report) and Ardelyx (ARDX – Research Report).

Cogent Biosciences (COGT)

In a report released today, David Nierengarten from Wedbush maintained a Hold rating on Cogent Biosciences, with a price target of $10.00. The company’s shares closed last Thursday at $8.95.

According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of 12.7% and a 45.7% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, Kiniksa Pharmaceuticals, and Fusion Pharmaceuticals.

Cogent Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $14.88.

See the top stocks recommended by analysts >>

Lantheus (LNTH)

JonesTrading analyst Justin Walsh maintained a Buy rating on Lantheus today and set a price target of $128.00. The company’s shares closed last Thursday at $65.05.

According to TipRanks.com, Walsh has 0 stars on 0-5 stars ranking scale with an average return of -9.6% and a 32.1% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Actinium Pharmaceuticals, and Fusion Pharmaceuticals.

Currently, the analyst consensus on Lantheus is a Strong Buy with an average price target of $98.00, a 55.6% upside from current levels. In a report issued on February 14, Leerink Partners also maintained a Buy rating on the stock with a $96.00 price target.

Ardelyx (ARDX)

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Ardelyx, with a price target of $13.00. The company’s shares closed last Thursday at $8.82.

According to TipRanks.com, Chico is a 4-star analyst with an average return of 3.6% and a 49.5% success rate. Chico covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ultragenyx Pharmaceutical, and Longboard Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ardelyx with a $12.79 average price target, which is a 46.7% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $11.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on COGT:

• Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
• Cogent Biosciences Launches $225M Private Stock Sale
• Cogent Biosciences announces oversubscribed $225M private placement
• Cogent Biosciences sells 17M shares at $7.50 in private placement
• Cogent Biosciences Announces Oversubscribed $225 Million Private Placement